The literature cluster reveals a maturing CAR-T field expanding along three simultaneous trajectories: target diversification, manufacturing innovation, and equity/safety optimization. Beyond established CD19-directed therapy for diffuse large B-cell and large B-cell lymphoma, engineering efforts now target antigens on acute myeloid leukemia cells (CD33, FLT3, CD70, CLL-1, TIM-3), novel alloantigens like mismatched HLA-DRB1 to address post-alloHCT relapse, and solid-tumor antigens such as mesothelin and MUC4 (validated in colorectal cancer models, where CAR-T eliminates chemoresistant HT29-MTX cells and delays subcutaneous tumor growth). This antigen expansion is paralleled by CAR NK cell therapy as an alternative modality, reviewed comprehensively by groups such as Osaka University, reflecting a broader push to diversify effector-cell platforms beyond autologous T cells.
A second major thread concerns overcoming the core biological barrier to solid-tumor efficacy: poor tumor infiltration. Chemokine receptor engineering—leveraging CXCR5, CCR2, CCR7, and the CXCL10 axis—emerges as a tractable enhancement strategy to redirect and concentrate CAR-T cells within tumors, a theme consolidated in dedicated reviews (e.g., International Immunopharmacology). Simultaneously, manufacturing is being reimagined through non-viral and mRNA-based strategies that serve as alternatives to viral-vector methods, reducing manufacturing cost, improving safety profiles, and enabling transient rather than permanent cellular modification via optimized mRNA design—innovations that also support decentralized point-of-care production with reported >90% cost reductions versus centralized manufacturing.
Safety and monitoring form a third convergent focus: cytokine release syndrome and neurotoxicity (including ICANS) remain central adverse effects tracked through harmonized cytokine and CAR-T kinetic biomarkers, flow cytometry, and droplet digital PCR, with protein biomarker panels predicting immune-related adverse events and hematologic toxicities/cytopenias recognized as distinct, manageable risks. Health-related quality of life trajectories (worsening before and improving after day 7) further refine peri-treatment management. Finally, structural equity concerns—racial, geographic, and socioeconomic disparities in CAR-T access and outcomes—are increasingly documented (e.g., Weill Cornell's access-barrier landscape analysis), alongside prognostic frameworks like IPI risk stratification guiding treatment sequencing (CAR-T versus alloSCT) for high-risk lymphoma patients. Together, these threads depict a field pivoting from proof-of-concept hematologic success toward broadened indications, safer/cheaper manufacturing, and equitable, biomarker-guided clinical deployment.